KOSDAQBiotech & Pharma299660

Cellid

₩1,733▲ 3.09%2026-11-18 close
Market Cap
₩51.1B
Turnover
₩2B
Volume
1.1M
Shares out.
29.5M
PER
—
PBR
—
EPS
-₩981
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Pipeline Reset After Phase 3 Miss, Losses Persist

Cellid is shifting its focus to cancer immunotherapy and partnership talks after its COVID-19 vaccine Phase 3 trial failed to show non-inferiority in June 2026, while the disclosed results show operating losses in each of the five quarters from 3Q 2025 through 3Q 2026.

  1. 1

    Disclosed 2025 revenue was KRW 8.84 billion, up 112.3% year on year, but the operating loss was KRW 11.3 billion, so the loss structure remains.

  2. 2

    On the cancer side, final results of the BVAC-C combination study were published in JITC on November 18, 2026, reporting a 37.9% objective response rate. The COVID-19 vaccine AdCLD-CoV19-1 OMI Phase 3 did not demonstrate non-inferiority on its primary immunogenicity endpoint, as disclosed on June 26, 2026.

  3. 3

    Equity raises have recurred since 2023, and a September 2026 third-party allotment made a new investor the largest shareholder.

  4. 4

    The net loss attributable to controlling shareholders was KRW 19 billion in 2Q 2026, and the four-quarter total from 4Q 2025 to 3Q 2026 was KRW 28.7 billion.

  5. 5

    Operating cash flow was negative in every year from 2022 to 2025, with a KRW 10.2 billion outflow in 2025.

02

Business structure

Cellid is a biotech venture founded in 2006 and listed on KOSDAQ in 2019. Its core technology is the CeliVax-based cancer immunotherapy vaccine line and infectious disease prophylactic vaccines, and it also runs CMO and CDMO operations through a GMP facility completed in 2020.

In cancer, BVAC-C completed an investigator-led study combined with AstraZeneca's PD-L1 inhibitor durvalumab in HPV-positive cervical cancer. BVAC-E6E7, aimed at head and neck cancer, is in a Phase 1/2a trial supported by KDDF, and the company said the first patient was dosed in March 2026.

On the infectious disease side, the adenoviral-vector COVID-19 vaccine AdCLD-CoV19-1 OMI was the lead candidate, but its global Phase 3 results fell short in June 2026. Revenue comes from a different base.

An e-commerce unit created through the 2024 merger of a bakery business sells baking ingredients and supplies online, and the company cited growth in contract manufacturing in 2025 as well. Press reports indicated the bakery unit accounted for 91% of 2024 revenue and 99.8% in 1Q 2025.

Among listed peers, SK Bioscience is a large vaccine comparison and Samsung Biologics a large CDMO comparison, but Cellid's commercial revenue base is thin, which makes direct comparison difficult.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.3B-₩2.5B−109.2%
2025Q4₩2.8B-₩3.7B−131.1%
2026Q1₩3.2B-₩1.6B−50.3%
2026Q2₩2.1B-₩2.5B−121.2%
2026Q3₩2.4B-₩3.1B−131.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩500M-₩14.9B-₩22.9B−3106.5%−101.9%104.4%
2023—-₩12.2B-₩11.6B—−28.7%57.9%
2024₩4.2B-₩12B-₩12.3B−287.6%−23.9%48.6%
2025₩8.8B-₩11.3B-₩12.1B−128.3%−16.3%49.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On the disclosed annual figures (separate-basis regular reports), revenue rose from KRW 480 million in 2022 to KRW 4.17 billion in 2024 and KRW 8.84 billion in 2025, up 112.3% year on year.

The company attributed the 2025 increase mainly to revenue growth in the e-commerce business unit absorbed through a merger in May 2024. Operating loss narrowed each year, from KRW 14.9 billion in 2022 to KRW 12.2 billion in 2023, KRW 12 billion in 2024 and KRW 11.3 billion in 2025.

The operating margin improved from -3,106.5% in 2022 to -287.6% in 2024 and -128.3% in 2025, but it remains deeply negative because revenue is small relative to costs.

Net loss attributable to controlling shareholders was KRW 22.9 billion in 2022, KRW 11.6 billion in 2023, KRW 12.3 billion in 2024 and KRW 12.1 billion in 2025, with the loss widening in 2024 and narrowing in 2025. Net income including non-controlling interests is disclosed with the same yearly values.

At end-2025, total equity was KRW 74.2 billion, all of it attributable to controlling shareholders, and total liabilities were KRW 36.7 billion. The debt-to-equity ratio moved from 104.4% in 2022 to 57.9% in 2023, 48.6% in 2024 and 49.4% in 2025, a pattern consistent with capital injections lowering leverage.

Operating cash outflows were KRW 12.2 billion in 2022, KRW 7.12 billion in 2023, KRW 10.3 billion in 2024 and KRW 10.2 billion in 2025.

Quarterly revenue rose from KRW 2.33 billion in 3Q 2025 to KRW 2.81 billion in 4Q 2025 (up 20.3% quarter on quarter) and KRW 3.21 billion in 1Q 2026 (up 14.5%), then fell to KRW 2.07 billion in 2Q 2026 (down 35.8%) before reaching KRW 2.37 billion in 3Q 2026 (up 14.7% quarter on quarter and up 1.5% year on year).

Operating losses were KRW 2.55 billion in 3Q 2025, KRW 3.68 billion in 4Q 2025, KRW 1.62 billion in 1Q 2026, KRW 2.5 billion in 2Q 2026 and KRW 3.11 billion in 3Q 2026, with the 3Q 2026 loss wider than a year earlier.

The net loss attributable to controlling shareholders reached KRW 19 billion in 2Q 2026, well above the other quarters in the table, and the same quarter included the Phase 3 disclosure. Line-item detail on one-time factors should be checked in the notes to the 2026 annual report.

The four-quarter total of net losses attributable to controlling shareholders from 4Q 2025 to 3Q 2026 was KRW 28.7 billion.

05

Industry analysis

Cellid operates in two distinct markets. Infectious disease vaccines involve long variant-response trials and approval procedures, while cancer immunotherapy increasingly centers on combinations with checkpoint inhibitors.

The investigators who led the BVAC-C combination study compared the response rate with the 10 to 26% objective response rates previously reported for checkpoint inhibitor monotherapy in second-line settings, calling the result encouraging.

They also said follow-up studies are needed given the small investigator-led trial with 29 evaluable patients. On the COVID-19 side, the Phase 3 shortfall means additional trial design is now required.

On IP, the company said its antigen stabilization platform has been granted patents in Korea, the United States, Japan, Russia and Vietnam, with decisions in China and India announced in October 2026, while its vector delivery platform has been registered in Korea, the United States and Europe.

Government support has continued as well: a head and neck cancer vaccine program was selected in the national drug development program in November 2025, and a program targeting five high-risk HPV types was selected for 2026, according to company announcements.

HPV-related therapeutic vaccines are pursued by several developers, so differentiation rests on clinical data. Against larger vaccine makers and CDMO companies, Cellid has fewer commercial products, and its pipeline value depends on clinical data and patent rights. Swings in demand for infectious disease vaccines also shape how revenue should be read.

06

Outlook

The company's disclosed and announced items fall into three groups. First, for the COVID-19 vaccine, Cellid is reviewing additional trial designs to address the Phase 3 immunogenicity result and said at the end of June 2026 that it would explain specific plans at a shareholder briefing.

Second, it is preparing an immunogenicity study of AdCLD-CoV19-1 XFG, which reflects the recommended variants for 2026 to 2027. Clinical trial material production is complete, and the company targets filing for trial approval in late 2026 or early 2027.

Third, in cancer, the company said it will firm up discussions with companies considering business cooperation based on the final BVAC-C results, while BVAC-E6E7 continues in its Phase 1/2a trial.

On financing, a KRW 10 billion investment and a roughly KRW 3 billion third-party allotment were disclosed in September 2026, and the company said it will pursue further funding to expand the business. Litigation is also a variable.

A claim seeking return of the bakery business was filed in January 2026 and is being handled through outside counsel.

In August 2026, the company announced a win in a trademark dispute and said the legal risk had entered a resolution phase, though that is the company's own framing and the final outcome of the lawsuit remains open.

No formal revenue or profit targets were identified in the company's guidance, so the most reliable baseline for quarterly results is the figures confirmed in the regular reports.

Factors supporting the case include the BVAC-C data, patent expansion and partnership talks, while factors weighing on it include the Phase 3 shortfall, the need for additional funding and the change in control.

07

Valuation

PER
—
PBR
—
ROE
-44.8%
EPS
-₩981
BPS
—
Dividend per share
₩0

Current valuation is difficult to read through earnings-based metrics. Because net losses have continued over the last four quarters, the price-to-earnings ratio cannot be calculated, and the company does not pay dividends.

On an asset basis, market capitalization sits below total equity at the end of 2025 (KRW 74.2 billion), so the shares trade at a discount to book net assets. However, equity includes the effect of rights issues, and how much of it converts into pipeline value is the central question.

Because share issuance has recurred since 2023, the share count has grown, and per-share comparisons need to account for dilution.

Comparisons with the historical valuation band are of limited use while operating losses persist, and sector comparisons are best made against other loss-making companies rather than profitable peers. The core of the valuation debate is how far pipeline progress and the terms of future funding become certain.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Accumulating combination immunotherapy data

Final results of the BVAC-C combination study with durvalumab were published in JITC on November 18, 2026. Among 29 evaluable patients, the objective response rate was 37.9%, the disease control rate 62.1%, and the median progression-free survival 8.7 months.

The investigators compared this with the 10 to 26% response rates reported for checkpoint inhibitor monotherapy in second-line settings. They also noted the small investigator-led scale and called for follow-up studies.

Partnership talks and government programs

A KRW 10 billion investment in September 2026 gave a new investor the largest shareholding, and the company said it will combine that investor's medical data with its cancer vaccine development. Cellid said it is firming up cooperation talks with companies that are considering partnerships based on the BVAC-C results.

In June 2026, a cancer vaccine targeting five high-risk HPV types was selected for the national drug development program, according to the company.

Overseas expansion of platform patents

The company said its antigen stabilization technology has been registered in Korea, the United States, Japan, Russia and Vietnam, with registration decisions in China and India announced in October 2026. Its adenoviral delivery platform has been registered in Korea, the United States and Europe.

Cellid plans to use these rights as support for its differentiation in overseas business and technology transfer talks. NK cell-related patents applied to its cancer immunotherapy also received registration decisions in the United States and Singapore in July 2026.

09

Bear factors

Phase 3 immunogenicity miss

The global Phase 3 trial of AdCLD-CoV19-1 OMI failed to show non-inferiority on its primary immunogenicity endpoint.

The share of participants with at least a four-fold rise in neutralizing antibody titers was 17.12% in the vaccine arm and 42.64% in the control arm, a difference of -25.51% that falls outside the -10% non-inferiority margin.

No serious adverse drug reactions were reported, but the company is reviewing additional trial designs. With further trials now needed, the timing of commercialization is uncertain.

Persistent losses and repeated equity raises

Operating losses have appeared in each of the five quarters from 3Q 2025 through 3Q 2026, and the four-quarter total of net losses attributable to controlling shareholders was KRW 28.7 billion. Operating cash flow was negative every year from 2022 to 2025.

Following a KRW 17.5 billion public offering in 2023 and a KRW 23.1 billion rights offering in August 2025, the company raised funds through a KRW 10 billion and an approximately KRW 3 billion third-party allotment in September 2026. Repeated issuance raises the risk of dilution for existing shareholders.

Revenue mix and litigation

Press reports indicated the bakery unit accounted for 91% of 2024 revenue and 99.8% in 1Q 2025, meaning the company's revenue flow is largely separate from its pipeline. A claim seeking return of the bakery business was filed in January 2026.

The 3Q 2026 operating loss of KRW 3.11 billion was wider than a year earlier, and quarterly swings in revenue and profit make the trend harder to read.

10

Risk factors

Clinical and regulatory risk

The COVID-19 vaccine requires further trials to address the Phase 3 immunogenicity result, and any delay in the trial approval application targeted for late 2026 or early 2027 would push back the whole timeline.

In cancer, BVAC-C results come from a small investigator-led study, and BVAC-E6E7 is at an early Phase 1/2a stage. Reproducibility of clinical results and regulatory discussions are the key variables.

Financing and dilution risk

Operating losses and cash outflows continue, so the company depends heavily on outside funding. Because the company said it will pursue further financing to expand the business, repeated share issuance would dilute existing holders.

The net loss attributable to controlling shareholders reached KRW 19 billion in 2Q 2026, and if the loss structure does not change, the funding burden may continue.

Governance and legal risk

A September 2026 transaction gave a new investor the largest shareholding and a change in control. At the March 2026 regular shareholder meeting, four special resolutions to amend the articles and the director compensation limit failed for lack of quorum.

The bakery business return lawsuit is ongoing, and although the company said the trademark win has eased legal risk, the final outcome of the lawsuit remains open.

11

What to watch next

  1. Late 2026 to early 2027 (company target)

    Confirm whether the trial approval application for AdCLD-CoV19-1 XFG is actually filed. The filing determines the timing of additional trials and the commercialization path for the COVID-19 vaccine.

  2. By March 31, 2027

    Check annual revenue, operating loss and operating cash flow in the 2026 annual report, and review the line-item breakdown of the KRW 19 billion net loss attributable to controlling shareholders in 2Q 2026 in the notes.

  3. After December 2026 (timing undetermined)

    Watch whether the cooperation talks based on the BVAC-C results lead to signed agreements. Contract terms and disclosure of the counterparties would show the external value of the cancer pipeline.

  4. After December 2026 (timing undetermined)

    Track the size and form of further financing and whether interim results from the BVAC-E6E7 Phase 1/2a trial are released. Whether funding relies mainly on share issuance will determine the dilution burden.

12

Overall view

Cellid's current position can be grouped into three areas. Disclosed revenue grew to KRW 8.84 billion in 2025, but the operating loss of KRW 11.3 billion and operating cash outflows continue.

In cancer, the BVAC-C combination results were published in a journal, adding data, while the COVID-19 vaccine missed non-inferiority in its June 2026 Phase 3 and needs further design. On funding, a September 2026 investment changed the largest shareholder, and further financing plans were disclosed at the same time.

Supporting factors are the cancer data, patent expansion and partnership talks, while weighing factors are continued losses, the Phase 3 miss, repeated equity raises and governance and litigation variables.

The next checkpoints are the trial approval filing for the COVID-19 vaccine between late 2026 and early 2027, and the operating loss and operating cash flow in the 2026 annual report due by March 31, 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. digitaltoday.co.kr
  2. comp.wisereport.co.kr
  3. news.nate.com
  4. comp.fnguide.com
  5. cellid.co.kr
  6. greened.kr
  7. hansbiz.co.kr
  8. innoforest.co.kr
  9. thevc.kr
  10. m.news.nate.com
  11. newspim.com
  12. fnnews.com
  13. cellid.co.kr
  14. m.news.nate.com
  15. m.news.nate.com
  16. news.nate.com
  17. fnnews.com
  18. view.asiae.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis